DK2739293T3 - Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus - Google Patents
Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus Download PDFInfo
- Publication number
- DK2739293T3 DK2739293T3 DK12746243.0T DK12746243T DK2739293T3 DK 2739293 T3 DK2739293 T3 DK 2739293T3 DK 12746243 T DK12746243 T DK 12746243T DK 2739293 T3 DK2739293 T3 DK 2739293T3
- Authority
- DK
- Denmark
- Prior art keywords
- vaccinavirus
- compositions
- production
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515724P | 2011-08-05 | 2011-08-05 | |
| PCT/US2012/049550 WO2013022764A1 (en) | 2011-08-05 | 2012-08-03 | Methods and compositions for production of vaccina virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2739293T3 true DK2739293T3 (da) | 2020-08-24 |
Family
ID=46650950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12746243.0T DK2739293T3 (da) | 2011-08-05 | 2012-08-03 | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9719105B2 (da) |
| EP (1) | EP2739293B1 (da) |
| JP (1) | JP6243333B2 (da) |
| KR (1) | KR102022952B1 (da) |
| CN (1) | CN103732236B (da) |
| AU (1) | AU2012294606B2 (da) |
| BR (1) | BR112014000787B1 (da) |
| CA (1) | CA2841831C (da) |
| DK (1) | DK2739293T3 (da) |
| ES (1) | ES2813413T3 (da) |
| PL (1) | PL2739293T3 (da) |
| WO (1) | WO2013022764A1 (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6895374B2 (ja) | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| CA2990133A1 (en) * | 2015-06-19 | 2017-03-09 | Sillajen, Inc. | Compositions and methods for viral embolization |
| CN106676071B (zh) * | 2015-11-06 | 2019-07-19 | 天士力创世杰（天津）生物制药有限公司 | HeLa-F细胞及其用途 |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| JP7110203B2 (ja) | 2016-12-28 | 2022-08-01 | トランジェーヌ | 腫瘍溶解性ウイルスおよび治療用分子 |
| EP4286009A3 (en) | 2017-04-21 | 2024-04-03 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| AU2018287159A1 (en) | 2017-06-21 | 2020-01-16 | Transgene | Personalized vaccine |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| JP2022508156A (ja) * | 2018-11-21 | 2022-01-19 | ウエスタン オンコリティクス リミテッド | ウイルスの製造 |
| US20220056481A1 (en) | 2018-12-28 | 2022-02-24 | Transgene | M2-defective poxvirus |
| KR102228267B1 (ko) | 2019-01-25 | 2021-03-17 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| AU2021297631A1 (en) | 2020-06-22 | 2023-02-02 | Kolon Life Science, Inc. | Method for mass-producing vaccinia virus by using suspension cells |
| AU2021309007A1 (en) | 2020-07-13 | 2023-02-16 | Transgene | Treatment of immune depression |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| KR20240004764A (ko) | 2021-04-30 | 2024-01-11 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 mhc 발현을 위한 종양용해성 바이러스 |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| CN114395538A (zh) * | 2022-01-19 | 2022-04-26 | 和元生物技术（上海）股份有限公司 | 一种促进重组病毒载体向细胞外分泌的方法 |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
| WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267965B1 (en) | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| IL154712A0 (en) * | 2000-11-23 | 2003-10-31 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| CN1754002B (zh) | 2002-08-12 | 2010-09-08 | 杰能斯有限公司 | 涉及痘病毒和癌的组合物及制备方法 |
| CA2602944C (en) * | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| JP2009507853A (ja) * | 2005-09-07 | 2009-02-26 | ジェンネレックス インコーポレイティッド | Ｇｍ−ｃｓｆ発現ポックスウイルスを用いる転移性および／または全身播種性癌の全身処置 |
| EP2055311B1 (en) * | 2006-08-07 | 2017-06-21 | The Chemo-Sero-Therapeutic Research Institute | Process for preparing live smallpox vaccine |
| KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US8003364B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
| WO2009048769A2 (en) * | 2007-10-10 | 2009-04-16 | Kirin Pharma Kabushiki Kaisha | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| JP2013500717A (ja) | 2009-07-28 | 2013-01-10 | コーニング インコーポレイテッド | 細胞を培養するための合成マイクロキャリア |
| EP3409119B1 (en) * | 2009-09-14 | 2020-08-12 | SillaJen Biotherapeutics, Inc. | Oncolytic vaccinia virus combination cancer therapy |
-
2012
- 2012-08-03 ES ES12746243T patent/ES2813413T3/es active Active
- 2012-08-03 BR BR112014000787-0A patent/BR112014000787B1/pt active IP Right Grant
- 2012-08-03 EP EP12746243.0A patent/EP2739293B1/en active Active
- 2012-08-03 JP JP2014524110A patent/JP6243333B2/ja active Active
- 2012-08-03 CA CA2841831A patent/CA2841831C/en active Active
- 2012-08-03 DK DK12746243.0T patent/DK2739293T3/da active
- 2012-08-03 KR KR1020147005901A patent/KR102022952B1/ko active IP Right Grant
- 2012-08-03 CN CN201280038029.8A patent/CN103732236B/zh active Active
- 2012-08-03 US US14/236,982 patent/US9719105B2/en active Active
- 2012-08-03 PL PL12746243T patent/PL2739293T3/pl unknown
- 2012-08-03 AU AU2012294606A patent/AU2012294606B2/en active Active
- 2012-08-03 WO PCT/US2012/049550 patent/WO2013022764A1/en active Application Filing
-
2017
- 2017-06-27 US US15/634,765 patent/US10202581B2/en active Active
-
2019
- 2019-02-07 US US16/270,585 patent/US10767166B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2739293A1 (en) | 2014-06-11 |
| US10202581B2 (en) | 2019-02-12 |
| CN103732236A (zh) | 2014-04-16 |
| CA2841831C (en) | 2019-12-31 |
| KR20140058601A (ko) | 2014-05-14 |
| PL2739293T3 (pl) | 2020-11-16 |
| AU2012294606B2 (en) | 2016-10-06 |
| BR112014000787A2 (pt) | 2017-07-11 |
| US9719105B2 (en) | 2017-08-01 |
| CN103732236B (zh) | 2017-09-15 |
| KR102022952B1 (ko) | 2019-09-20 |
| JP2014521353A (ja) | 2014-08-28 |
| US20140162342A1 (en) | 2014-06-12 |
| WO2013022764A1 (en) | 2013-02-14 |
| BR112014000787B1 (pt) | 2021-04-13 |
| US20170298324A1 (en) | 2017-10-19 |
| US10767166B2 (en) | 2020-09-08 |
| AU2012294606A1 (en) | 2014-01-23 |
| ES2813413T3 (es) | 2021-03-23 |
| EP2739293B1 (en) | 2020-06-10 |
| US20190169578A1 (en) | 2019-06-06 |
| JP6243333B2 (ja) | 2017-12-06 |
| CA2841831A1 (en) | 2013-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2739293T3 (da) | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus | |
| DK2872153T3 (da) | Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf | |
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK2768321T3 (da) | Fremgangsmåder og sammensætninger til induktion af mæthed | |
| DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3702443T3 (da) | Sammensætninger og fremgangsmåder til opformering og dyrkning af epiteliale stamceller | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK3421051T3 (da) | Fremgangsmåder til glycokonjugering og sammensætninger | |
| DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
| DK2718404T3 (da) | Fremgangsmåde til fremstilling af flydende carbonhydrider | |
| DK2736837T3 (da) | Fremgangsmåde til fremstilling af nanosiliciumtråde | |
| DK3824991T3 (da) | Fremgangsmåde til forberedelse af lithiumsulfat | |
| DK2533761T3 (da) | Fremgangsmåder og sammensætninger til fremstilling af aerosoler | |
| DK3141548T3 (da) | Fremgangsmåder og mellemprodukter til fremstilling af azaindoler | |
| DK3210978T3 (da) | Fremgangsmåde til fremstilling af acesulfamkalium | |
| DK2758349T3 (da) | Vanadiumbaserede frittematerialer og fremgangsmåder til fremstilling heraf | |
| UY4115Q (es) | Reloj | |
| BR112014010450A2 (pt) | composição e método | |
| DK3077513T3 (da) | Sammensætninger og fremgangsmåder til fremstilling af (r)-retikulin og udgangsstoffer deraf | |
| DK2785801T4 (da) | Fremgangsmåde til formindskelse af isdannelse på et underlag | |
| DK2627656T3 (da) | Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf | |
| DK3299356T3 (da) | Fremgangsmåde til fremstilling af pleuromutiliner | |
| DK2800572T3 (da) | Sammensætning af ellagitannin-rige ekstrakter | |
| DK2836460T3 (da) | Fremgangsmåde til fremstilling af graphen | |
| DK2661274T3 (da) | Sammensætninger og fremgangsmåder med aloepolysaccharider |